Bio News

U.S.-based Beacon Therapeutics said its gene therapy laruparetigene zovaparvovec for a rare vision-loss disorder improved vision in a pivotal trial.
In the phase 2/3 VISTA study, 31% of patients in the high-dose group met the response criterion of reading at least 15 additional letters on a low-luminance visual acuity test.
Beacon Therapeutics plans to complete a rolling biologics license application with the U.S. Food and Drug Administration (FDA) by the end of the year.

Biobook Team
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%